SCHEDULE: Armistice Capital Reports 4.99% Stake in Bluejay Diagnostics

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 51,061 shares, representing 4.99% of the outstanding common stock of Bluejay Diagnostics, Inc.

Summary

• Armistice Capital, LLC and Steven Boyd have filed an amendment to their Schedule 13G filing.
• They collectively beneficially own 51,061 shares of Bluejay Diagnostics, Inc. common stock.
• This ownership stake represents 4.99% of the class of securities.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd is the managing member of Armistice Capital, LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership without any specific operational or financial performance indicators.

Positives

• Armistice Capital, LLC and Steven Boyd have disclosed their beneficial ownership, providing transparency to the market.
• The ownership stake of 4.99% is just below the 5% threshold that would trigger more stringent reporting requirements.

Negatives

• The filing does not contain any negative financial or operational information about Bluejay Diagnostics, Inc.

Risks

• The filing does not explicitly mention any risks associated with Bluejay Diagnostics, Inc.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• Armistice Capital, LLC exercises voting and investment power over the securities held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities held by the Master Fund.
• The Master Fund disclaims beneficial ownership of the securities directly held by it due to its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in public companies. This filing indicates Armistice Capital's interest in Bluejay Diagnostics, Inc., a development that investors will monitor for potential future strategic actions.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership stakes may influence investor sentiment and trading activity.
• Management of Bluejay Diagnostics, Inc.: Awareness of a substantial beneficial owner may inform strategic decisions and communications.

Next Steps

• Armistice Capital, LLC and Steven Boyd will be responsible for the timely filing of any subsequent amendments to this Schedule 13G.

Key Dates

Keywords

Schedule 13G, Bluejay Diagnostics, Armistice Capital, Steven Boyd, Beneficial Ownership, Common Stock, SEC Filing, Investment Management